New quinazoline sulfonamide derivatives as potential anticancer agents: Identifying a promising hit with dual EGFR/VEGFR-2 inhibitory and radiosensitizing activity.

[1]  M. El-Zahabi,et al.  Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis , 2023, Archiv der Pharmazie.

[2]  M. Ghoneim,et al.  Design, synthesis, and docking of novel thiazolidine‐2,4‐dione multitarget scaffold as new approach for cancer treatment , 2023, Archiv der Pharmazie.

[3]  M. El-Zahabi,et al.  Design, synthesis, anticancer evaluation, in silico docking and ADMET analysis of novel indole-based thalidomide analogs as promising immunomodulatory agents. , 2023, Journal of biomolecular structure & dynamics.

[4]  I. Eissa,et al.  Immunomodulatory quinazoline-based thalidomide analogs: Design, synthesis, apoptosis and anticancer evaluations , 2023, Journal of Molecular Structure.

[5]  Riham F. George,et al.  Exploration of thiazolidine‐2,4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations , 2022, Archiv der Pharmazie.

[6]  F. Ragab,et al.  Antiproliferative, antiangiogenic and apoptotic effect of new hybrids of quinazoline-4(3H)-ones and sulfachloropyridazine. , 2022, European journal of medicinal chemistry.

[7]  Xi Chen,et al.  Design, Synthesis and Antitumor Activities of Novel Quinazolinone Derivatives as Potential EGFR Inhibitors. , 2022, Chemical & pharmaceutical bulletin.

[8]  Riham F. George,et al.  Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors. , 2022, Bioorganic chemistry.

[9]  Reihane Ghomashi,et al.  Recent Advances on Biological Active Sulfonamide based Hybrid Compounds Part A: Two-Component Sulfonamide Hybrids. , 2022, Current medicinal chemistry.

[10]  Riham F. George,et al.  Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFRT790M tyrosine kinase inhibitors , 2022, RSC advances.

[11]  M. Abdelgawad,et al.  Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARγ Agonists , 2022, Pharmaceuticals.

[12]  Shengmin Shi,et al.  Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-). , 2021, European journal of medicinal chemistry.

[13]  I. Eissa,et al.  Phthalazine‐based VEGFR‐2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations , 2021, Archiv der Pharmazie.

[14]  S. Salama,et al.  Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents. , 2021, Bioorganic chemistry.

[15]  C. Supuran,et al.  Biological evaluation, radiosensitizing activity and structural insights of novel halogenated quinazoline-sulfonamide conjugates as selective human carbonic anhydrases IX/XII inhibitors. , 2021, Bioorganic chemistry.

[16]  M. Abdel-Kader,et al.  Synthesis of some quinazolinones inspired from the natural alkaloid L-norephedrine as EGFR inhibitors and radiosensitizers , 2020, Journal of enzyme inhibition and medicinal chemistry.

[17]  M. Kamal,et al.  Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions. , 2020, Current drug metabolism.

[18]  K. Wagner,et al.  PPARs and Angiogenesis—Implications in Pathology , 2020, International journal of molecular sciences.

[19]  K. Abouzid,et al.  Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors. , 2020, Bioorganic chemistry.

[20]  C. Supuran,et al.  Iodoquinazolinones bearing benzenesulfonamide as human carbonic anhydrase I, II, IX and XII inhibitors: Synthesis, biological evaluation and radiosensitizing activity. , 2020, European journal of medicinal chemistry.

[21]  A. Foroumadi,et al.  A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. , 2020, Bioorganic chemistry.

[22]  Ahmed M. El Kerdawy,et al.  Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents. , 2020, Bioorganic chemistry.

[23]  I. Eissa,et al.  Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR‐2 inhibitors , 2019, Archiv der Pharmazie.

[24]  A. Alqahtani,et al.  Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers , 2019, Journal of enzyme inhibition and medicinal chemistry.

[25]  M. Alsaid,et al.  Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers. , 2018, Bioorganic chemistry.

[26]  A. Karsan,et al.  Evidence-based best practices for EGFR T790M testing in lung cancer in Canada. , 2018, Current oncology.

[27]  Kongming Wu,et al.  EGFR-TKIs resistance via EGFR-independent signaling pathways , 2018, Molecular Cancer.

[28]  Mamdouh M. Ali,et al.  Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR‐2 Inhibitors , 2017, Archiv der Pharmazie.

[29]  F. Ragab,et al.  Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors. , 2017, European journal of medicinal chemistry.

[30]  M. Alsaid,et al.  Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors , 2017, Journal of enzyme inhibition and medicinal chemistry.

[31]  D. Frezzetti,et al.  VEGF as a potential target in lung cancer , 2017, Expert opinion on therapeutic targets.

[32]  Mamdouh M. Ali,et al.  Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. , 2017, European journal of medicinal chemistry.

[33]  Xueyan Yu,et al.  EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer , 2017, Oncotarget.

[34]  F. Ragab,et al.  Aromatase inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and molecular modeling studies of novel phenothiazine derivatives carrying sulfonamide moiety as hybrid molecules. , 2017, European journal of medicinal chemistry.

[35]  Li‐Ping Sun,et al.  Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. , 2017, European journal of medicinal chemistry.

[36]  F. Ragab,et al.  VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety , 2017, Journal of enzyme inhibition and medicinal chemistry.

[37]  P. Kulkarni,et al.  5-Benzylidene-2,4-thiazolidenedione derivatives: Design, synthesis and evaluation as inhibitors of angiogenesis targeting VEGR-2. , 2016, Bioorganic chemistry.

[38]  Philip J. Chapman,et al.  The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity , 2016, European journal of medicinal chemistry.

[39]  Rui M. V. Abreu,et al.  Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. , 2015, Bioorganic & medicinal chemistry.

[40]  V. Torri,et al.  Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. , 2015, Critical reviews in oncology/hematology.

[41]  R. Wahl,et al.  Chemotherapy and Chemoprevention by Thiazolidinediones , 2015, BioMed research international.

[42]  C. Ramaa,et al.  A new dawn for the use of thiazolidinediones in cancer therapy , 2014, Expert opinion on investigational drugs.

[43]  Huan-qiu Li,et al.  Epidermal growth factor receptor inhibitors: a patent review (2010 – present) , 2014, Expert opinion on therapeutic patents.

[44]  F. Totzke,et al.  Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. , 2014, European journal of medicinal chemistry.

[45]  W. Pao,et al.  Targeted therapies: Afatinib—new therapy option for EGFR-mutant lung cancer , 2013, Nature Reviews Clinical Oncology.

[46]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[47]  A. Dahan,et al.  Oral Delivery of Lipophilic Drugs: The Tradeoff between Solubility Increase and Permeability Decrease When Using Cyclodextrin-Based Formulations , 2013, PloS one.

[48]  Yoshikazu Ohta,et al.  Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors. , 2013, ACS medicinal chemistry letters.

[49]  D. Ingber,et al.  Forty-Year Journey of Angiogenesis Translational Research , 2011, Science Translational Medicine.

[50]  Xiaoyuan Chen,et al.  Integrin Targeted Delivery of Radiotherapeutics , 2011, Theranostics.

[51]  Kyungik Lee,et al.  Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. , 2010, European journal of medicinal chemistry.

[52]  Paul Dent,et al.  Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[53]  L. Byers,et al.  Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. , 2007, Clinical lung cancer.

[54]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[55]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[56]  D. Shima,et al.  VEGF function in vascular pathogenesis. , 2006, Experimental cell research.

[57]  E. Scholar,et al.  Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[58]  D. Schuppan,et al.  Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. , 2005, Journal of hepatology.

[59]  Sui Huang,et al.  PPARγ as a therapeutic target for tumor angiogenesis and metastasis , 2005 .

[60]  V. Boddi,et al.  Correlation of Epidermal Growth Factor Receptor Expression with Tumor Microdensity Vessels and with Vascular Endothelial Growth Factor Expression in Ovarian Carcinoma , 2005, International journal of surgical pathology.

[61]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[62]  Susan M. Kilroy,et al.  PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. , 2002, The Journal of clinical investigation.

[63]  C. Arteaga.  Epidermal growth factor receptor dependence in human tumors: more than just expression? , 2002, The oncologist.

[64]  P. Furet,et al.  Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. , 1999, Pharmacology & therapeutics.

[65]  W. Clark,et al.  Biomarkers for individual susceptibility to carcinogenic agents: excretion and carcinogenic risk of benzo[a]pyrene metabolites. , 1992, Environmental health perspectives.

[66]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[67]  Khaled El-Adl,et al.  Pyrazolo[3,4-d]pyrimidine derivatives as EGFRT790M and VEGFR-2 dual TK inhibitors: Design, synthesis, molecular docking, ADMET profile and anticancer evaluations , 2023, Journal of Molecular Structure.

[68]  R. Salgia,et al.  Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation , 2006, Nature Clinical Practice Oncology.

[69]  L. Ellis,et al.  Vascular endothelial growth factor receptors: expression and function in solid tumors. , 2004, Clinical advances in hematology & oncology : H&O.

[70]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[71]  M. Shibuya,et al.  Structure and function of vascular endothelial growth factor receptor-1 and -2. , 1999, Current topics in microbiology and immunology.

[72]  J C Bailar,et al.  Cancer undefeated. , 1997, The New England journal of medicine.